Overview:<\/strong> Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor, usually described as an SNRI antidepressant. It is the active metabolite of venlafaxine but is marketed and prescribed as a separate medicine. This does not make the two drugs interchangeable or suitable for taking together. The information here refers to the US Pristiq extended-release tablet label.<\/p>\n Uses and formulation:<\/strong> The reviewed US indication is major depressive disorder in adults, not treatment of depression in children. Tablets are swallowed whole rather than crushed, split or dissolved. Kidney and liver function can affect the treatment plan. Benefits and tolerability should be reviewed with the prescriber; increasing the dose or stopping suddenly is not a safe way to manage a disappointing response.<\/p>\n Safety:<\/strong> Important concerns include worsening suicidal thoughts, serotonin syndrome, increased blood pressure, bleeding and low blood sodium. Urgent symptoms can include fever with agitation and muscle changes, a seizure, severe bleeding or sudden eye pain. Pregnancy and breastfeeding require an individual discussion. Small breastfeeding studies and pregnancy information from venlafaxine do not prove that every exposure is safe.<\/p>\n Drug interactions:<\/strong> MAO inhibitors require carefully planned separation intervals. Other serotonergic drugs, including some antidepressants, triptans, tramadol and lithium, can increase serotonin toxicity risk. NSAIDs, aspirin, antiplatelets and anticoagulants warrant bleeding surveillance. Some CYP2D6 interactions are dose-dependent and should not be presented as inevitable harm at the usual prescribed dose. Avoid alcohol and let a pharmacist check all current medicines before any change.<\/p>\nSources<\/h2>\n